Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15116722 | 0.79 | — | — | |
| SCHEMBL15116908 | 0.76 | FABP4 (0.30) | — | |
| SCHEMBL19388477 | 0.76 | — | — | |
| SCHEMBL15125205 | 0.75 | — | — | |
| SCHEMBL20054420 | 0.75 | DGAT1 (0.36) | CTSK | |
| SCHEMBL16391173 | 0.71 | CTSL (0.34) | CTSS | |
| SCHEMBL19388569 | 0.68 | CTSS (0.33) | CTSS | |
| SCHEMBL12667379 | 0.67 | ALDH1A1 (0.34) | — | |
| SCHEMBL17916094 | 0.66 | — | — | |
| SCHEMBL12397097 | 0.66 | ALDH1A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9717712-B2 | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-01 | — | — | US | disclosed |
| US-9717712-B2 | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160166547-A1 | Combinations Comprising Tricyclohexadecahexaene Derivatives for Use in the Treatment of Hepatitis C Virus | BRISTOL MYERS SQUIBB CO (US) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166547-A1 | Combinations Comprising Tricyclohexadecahexaene Derivatives for Use in the Treatment of Hepatitis C Virus | HAVCR2, HCCS, MAVS | CTSS 1517/4885CTSK 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.